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Abstract
Objective: Assess the outcome of neoadjuvant chemotherapy using Adriamycin and Cyclophosphamide 
followed by Paclitaxel (AC-P regime) in breast cancer.
Methods: A prospective observational study of newly diagnosed breast cancer patients with palpable 
breast lumps on neoadjuvant chemotherapy of AC-P regime. Age of the patients, tumour size, stage, 
estrogen, progestogen and HER2 receptor status were noted. Tumour size measured at presentation, first, 
third, fifth, sixth and eighth doses to determine response as defined by the UICC method i.e. complete 
clinical response, partial clinical response, stable disease and progressive disease.  
Results: Complete clinical response was observed in 40% of 35 patients studied. Complete clinical 
response was found in 81.8% tumours less than 5cm in diameter while 20.8% of  tumours greater 5cm.had 
2 
complete clinical response. (X =11.6, p= 0.001) Eighty-eight percent complied with treatment schedule. 
Mastectomy was done in 34.2%, Breast conservation surgery (BCS) in 14.2%, and 17.1% lost to follow 
up.
Conclusion: Neoadjuvant chemotherapy using AC-P sequential regime is effective in breast cancer with 
tolerable side effects and excellent treatment compliance in the study population.
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Réponse à la chimiothérapie néoadjuvante dans le cancer du sein dans 
un environnement aux ressources limitées.
Resume
Objectif: Évaluer les résultats de la chimiothérapie néoadjuvante utilisant de l’Adriamycine et du 
Cyclophosphamide, suivis du Paclitaxel (régime AC-P) dans le cancer du sein.
Méthodes: Une étude observationnelle prospective de patientes nouvellement diagnostiquées avec un 
cancer du sein présentant des masses mammaires palpables sous chimiothérapie néoadjuvante du régime 
AC-P. L'âge des patients, la taille de la tumeur, le stade, l'œstrogène, le progestogène et le statut des 
récepteurs HER2 ont été notés. Taille de la tumeur mesurée lors de la présentation des première, troisième, 
cinquième, sixième et huitième doses afin de déterminer la réponse définie par la méthode UICC, à savoir 
une réponse clinique complète, une réponse clinique partielle, une maladie stable et une maladie 
évolutive.
Résultats: Une réponse clinique complète a été observée chez 40% des 35 patients étudiés. Une réponse 
clinique complète a été trouvée dans 81,8% des tumeurs de moins de 5 cm de diamètre, tandis que 20,8% 
des tumeurs de plus de 5 cm avaient une réponse clinique complète. (  = 11,6, p = 0,001) Quatre-vingt-
huit pour cent ont respecté le programme de traitement. La mastectomie a été pratiquée dans 34,2% des 
cas, la chirurgie mammaire conservatrice (BCS) dans 14,2% des cas et 17,1% ont été perdus de vue.
Conclusion: La chimiothérapie néoadjuvante à l'aide du traitement séquentiel AC-P est efficace dans le 
cancer du sein, avec des effets secondaires tolérables et une excellente observance du traitement dans la 
population étudiée.
Mots-clés: chimiothérapie néoadjuvante, cancer du sein, réponse clinique, compliance, ressources 
limitées
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INTRODUCTION
Breast cancer incidence is rising in the 
low-income countries (LIC) with attendant 
increase in mortality and morbidity (1,2). In the 
high-income countries (HIC) the incidence is 
higher but the mortality and morbidity is less (2). 
Many reasons have been adduced for this which 
includes early diagnosis facilitated by screening 
programmes, widespread breast cancer 
awareness, prompt and effective treatment in the 
HIC. (1,2,3). Whereas in the LIC the disease is 
characterized by late presentation, coupled with  
inadequate or non-available facilities for 
diagnosis and treatment with attendant high 
mortality and morbidity (3).
Treatment of breast cancer (BC) should 
be done by a multidisciplinary team consisting of 
surgeons, radiotherapist, medical oncologist, 
physiotherapist, pharmacist, radiologist, and 
oncology nurses(4). It basically consists of loco-
regional disease control, prevention of systemic 
recurrence and control of metastases. Loco-
regional control can be achieved by surgery with 
or without radiotherapy whereas prevention and 
control of systemic disease is usually by 
chemotherapy, use of biologics or hormonal 
therapy while radiotherapy is useful in control of 
pain of osseous metastases. 
Adjuvant chemotherapy is systemic treatment 
applied post operatively while neoadjuvant 
chemotherapy is same treatment applied 
preoperatively. Neoadjuvant chemotherapy is 
now commonly used in locally advanced breast 
cancer.
Neoadjuvant chemotherapy reduces the 
tumour size and may render locally advanced 
disease amenable to surgical control (5,6,7), and 
permit breast conservation surgery in cases hither 
to considered unsuitable prior to neoadjuvant 
chemotherapy(5,6,7). Another advantage of 
neoadjuvant chemotherapy is the opportunity to 
assess tumour response to the drugs being applied 
(5,6,7). Despite these advantages there is no 
difference in overall survival in patents who had 
adjuvant therapy and those who had neoadjuvant 
chemotherapy (7).
There are many chemotherapy regimens 
for breast cancer therapy, from single agent to 
combination therapy. Choice of the agents and 
regime used depends on the aims of therapy, the 
stage of the disease, the hormone(oestrogen and 
progestogen)and HER 2 receptors status, the 
physiological status of the patient, availability 
and affordability(8). Many of the agents and 
regimes adopted for use in the developing world 
were selected from clinical trials conducted in the 
developed world.
In the developed world the advent of 
newer drugs and the practice of personalised 
medicine has reduced morbidity and mortality of 
breast cancer.  The high cost, non-availability of 
these drugs and practices has been a major 
impediment to their use in the developing 
countries (9). 
Most of our patients present with locally 
advanced breast cancer who often require 
neoadjuvant chemotherapy using regimes whose 
effectiveness were based on clinical trials among 
Caucasians. 
The aim of our study was to assess the outcome of 
neoadjuvant chemotherapy in the management of 
breast cancer in our practice. 
Objectives:
1.Assessment of clinical  response to 
chemothe rapy  r eg ime  Adr i amyc in ,  
Cyclophosphamide, followed by Paclitaxel 
(AC-P), in neoadjuvant therapy for breast 
cancer in our clinical setting.
2. To identify common side effects.
3. Factors affecting drug compliance. 
There is paucity of data on the outcome 
of neoadjuvant chemotherapy using these agents 
in patients with breast cancer. We are not aware of 
any previous study assessing neoadjuvant 
chemotherapy in our locality. The regimes were 
chosen on account of effectiveness among 
Caucasian population, low cost and easy 
availability in the country compared to other 
regimes.
MATERIALS AND METHODS
This is a prospective observational study 
of patients on neoadjuvant chemotherapy for 
newly diagnosed breast cancer patients with 
palpable lumps attending Olabisi Onabanjo 
University Teaching Hospital Sagamu, Breast, 
stEndocrine and Surgical Oncology unit from 1  
st
July 2017 to 31   December 2018.
The study was approved by the Hospital 
Ethics Review Committee and patients written 
consent were obtained,
Inclusion criteria:  All patients with 
histologically confirmed breast cancer and 
palpable mass on neoadjuvant chemotherapy 
who consented. 
Exclusion criteria: Patients who declined 
consent, those with metastatic disease, and those 
who were judged clinical unfit were excluded.
Res. J. of Health Sci. Vol 7(2), April/June 2019                                                          84
Neoadjuvant chemotherapy in breast cancer treatment outcome                          Ayoade et al.
The demographic characteristics of the patients 
were noted, symptoms and duration at 
presentation, findings on clinical examination 
with particular attention to the breasts stating 
lump size measured at the widest diameter and its 
perpendicular diameter using calipers, site, state 
of axillary nodes, clinical staging by TNM/AJCC 
method(10), histological type and grading, 
ER,PR, and HER II receptors status. Routine 
investigations to assess fitness for chemotherapy 
like FBC, E&U, ECG , chest x-ray were done. 
These are all routine investigations adopted in our 
practice. 
The regime of four courses of  I.V. 
A d r i a m y c i n  6 0  m g / m 2  a n d  I . V  
Cyclophosphamide 600mg/ m2  at three weekly 
interval was followed by four courses of I.V 
paclitaxel 175mg/ m2 at three weekly interval 
with the standard precautions of premedication 
with dexamethasone and metoclopramide (11). 
The routine investigations of FBC, E&U and LFT 
was done before each cycle.
Response to the therapy was assessed by 
measuring the size of the lump at its widest 
diameter and its  perpendicular diameter after the 
first dose, the third dose, sixth (at the 
commencement of the next dose) and last dose by 
the principal investigator or the first co-
investigator who have been doing this as part of 
our routine practice. The response to therapy was 
assessed using the UICC method consisting of the 
four categories: complete clinical response, 
partial clinical response, stable disease and 
progressive disease.(12) Patients who show 
progressive disease on this regime who were not 
suitable for surgical treatment were referred to 
the Radiotherapist /Oncologist . Side effects 
observed were noted.  The above is our normal 
protocol for administration of Neoadjuvant 
therapy.
Compliance with the regime and reasons 
for non-compliance were noted which were 
assessed at each follow up visit.
Data collection: Data were collected on 
specially designed forms and subsequently 
analyzed using SPSS software version 20.
Data analysis: SPSS Software was used to 
analyze outcome measures such as response to 
therapy in four UICC categories which were 
further classified as good clinical response which 
consists of complete clinical response or poor 
clinical response which consists of partial clinical 
response, stable disease and progressive disease, 
frequency of side effects, compliance/adherence 
and reasons for non-adherence using 
percentages, Chi square to test the significance of 
the association  of the paired categorical 
variables and level of significance set at p< . 05
RESULTS
Thirty-five female patients were seen 
during the study period. Their age range was 33-
82 years and mean age of 48 with Standard 
deviation (SD)of 11, 37.1% were in the 41 to 50 
years age bracket. Forty percent had education up 
to secondary school level, 65.7% were 
premenopausal, 62.9% were traders   The rest of 
the demographic features are as in Table 1. The 
presenting symptom was lump in the breast in all 
the patients but one had a nipple discharge and the 
lump was ulcerated in 17.6%. The range of 
symptoms duration was 1-24 months, (mean 7.5 
months, SD 6.5months), lump size range was 2-
24cm (mean 11.3cm, SD 7.5cm).  Twenty-nine 
patients (82.9%) had AJCC Stage III disease, the 
rest as in Table 2. All the patients had invasive 
ductal carcinoma. All the patients had between 
six to eight courses of chemotherapy of the AC-P 
regime.
The overall clinical response rate to 
neoadjuvant chemotherapy in this study was 
80%, consisting of complete clinical response of 
40% and partial clinical response 40%. Stable 
disease and progressive disease were observed in 
8.6% and 11.4% of the patients respectively. 
Complete clinical response observed in 40% was 
classified as Good clinical response and Partial 
response  observed in 40%, Stable disease in 
8.6% and Progressive disease in 11.4% were 
classified as Poor clinical response. The 
comparison of complete clinical response and 
clinical parameters is shown in Table 3. The 
clinical response in the AJCC stage and 
immunohistochemistry is as shown in Table 3.
The most common side effects of the 
drugs were, nausea, alopecia, hyperpigmentation 
of the hands and feet and the rest as shown in 
Table 4.Thirty-one patients (88.6%) complied 
with the treatment protocol while four did not. 
Reason for non-compliance was cost in 3 
patients(8.6%) and side effects in one patient. 
Mastectomy was done in 12patients (34.2%), 
Breast conservation surgery in 5patients (14.2%), 
7patients (20%) are awaiting surgery as at the 
time of this report, 5patients (14.2%) were 
referred to Radiation oncologist, 6patients 
(17.1%) absconded from follow up of which 3 
had complete clinical response.
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DISCUSSION
The majority of patients in this study 
were premenopausal women with mean age of 48 
years  and over a third of them in the 41-50 years 
age bracket. This is consistent with observed age 
incidence in breast cancer in sub Saharan Africa 
unlike in the western world where older women 
are more affected(13).  The cohort also consisted 
of mostly patients with locally advanced disease, 
a group in which neoadjuvant chemotherapy is 
strongly indicated. Late presentation evidenced 
by long duration of symptoms and presence of 
large palpable lumps as seen in this study is the 
usual occurrence(3), moreover this observation is 
expected since one of the inclusion criteria is the 
presence of palpable lumps.
The overall clinical response observed in 
this study compares favourably with findings of 
Awad Ali  in Sudan who found a clinical response 
rate of 83% in a prospective study of 98 patients 
on chemotherapy(14), and other workers (15). 
This demonstrates the effectiveness of these 
agents in reducing the gross tumour size in the 
study population. This is at variance with the 
findings of Arowolo et al in a retrospective 
review of 62 breast cancer cases on neoadjuvant 
chemotherapy seen over a 24 year period in 
which clinical response was observed in 51.7% of 
the patients(16). 
Complete clinical response was 
observed in 40% of the patients, this is 
comparable to values quoted by other workers for 
Adriamycin and cyclophosphamide combination 
chemotherapy (17,18) though our regime 
included four 3 weekly course of paclitaxel, a 
taxane which has been found to improve clinical 
response.(19). Clinical response determined by 
palpation or by radiological investigations like 
ultrasound, mammography or Breast MRI may 
not accurately assess presence or absence of 
residual tumour after neoadjuvant chemotherapy 
since residual fibrosis or tissue oedema may 
occur and also patchy or scattered tumour residue 
may be present.(17,18,20). A better measure of 
response to neoadjuvant chemotherapy is 
complete pathological response which is 
determined by histopathological examination of 
postoperative specimen for residual tumour after 
neoadjuvant therapy. Complete pathological 
response after neoadjuvant chemotherapy has 
been associated with prolonged disease free 
period and better overall survival.(21)  One of the 
advantages of neoadjuvant therapy is the in vivo 
demonstration of efficacy of the drugs and 
appropriate measures can be instituted when 
there is lack of efficacy to avoid futile 
treatment(22). In this study, 20% of the patients 
showed  either stable or progressive disease 
interpreted as no response and those not suitable 
for surgical treatment were promptly referred to 
Radiotherapist/ Clinical oncologist.
Several factors have been studied to 
predict clinical response to neoadjuvant 
chemotherapy such as age, menstrual status, size 
of tumour, stage of disease, tumour grade, ER, 
PR, HERII, Ki67, apoptosis related gene p53, bcl-
2 and BAX but so far the data available is 
limited(23).  In our study 70% of the patients 
aged 40years and below had good clinical 
response compared to 28% in patients aged above 
forty years, also 52.2% of patient who were 
premenopausal had good clinical response 
compared with 16.6% in post menopausal 
women,( both of this observation were 
statistically significant).Good clinical response 
by younger patients as seen in our study has been 
reported by other researchers (24,25). Good 
clinical response was observed in 81.8% of 
patients with tumours less than 5cm in diameter, 
compared to 20.8% with good clinical response 
in those with tumours greater than 5cm in 
diameter, this was statistically significant Chi 
squared 11.6 , p =.001. Bonadonna et al observed 
similar findings in which, tumour size had an 
inverse relationship to complete clinical 
response.(26). The reason is likely related to the 
fact that smaller tumours usually have larger 
growth fraction consisting of rapidly dividing 
cells which are principally affected by 
chemotherapeutic agents. This is also reflected in 
the observation that all the Stage 2 tumours had 
good clinical response compared with 27.6% (8 
0f 29)  cases with stage 3 tumours.
Triple negative breast cancer (TNBC), 
hormone receptor negative and HER II positive 
breast tumours show good response to 
neoadjuvant chemotherapy (27) , but in our study 
only 25% (3of 12) cases of TNBC had good 
response compared with Non-TBNC tumours 
46%(6 of 13) had good clinical response. This 
observation may be due to the small number of 
cases studied which was reduced further by 
unavailability of immunohistochemistry result 
for 28.6% (10 of 35) of the cases.
The common side effects observed in this 
study included gastrointestinal symptoms like 
vomiting and anorexia, hyperpigmentation of the 
hands and feet, and alopecia which was almost 
universal, similar to observation of Clegg-
Lamptey et-al in Ghana and Fisher et.al(28,29).  
These  s ide  e ffec t s  occur red  desp i te  
administration of metoclopramide  and 
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Table 1: Demographic features  
 
 Frequency Percentage (%) 
Age groups (years) 
    < 40 
    41-50 
    51-60 
    61-70 

















    Premenopausal 











    No formal education 
    Primary 
    Secondary 















    Trading 
    Civil servant 
    Teaching 
    Artisan 
    Unemployed 


























Table 2. AJCC stage and Immunohistochemistry 
 
 Frequency Percentage (%) 
AJCC Stage 
            I 
            II 
            III 
      Total 
 
  2 









          TNBC  
Er+, Pr+, HER+  
Er+ ,Pr +, HER-  
Er-, Pr-, HER+  
Er+, Pr-, Her-  
     Total  
 
12 
  3 
  2 
  7 
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Table 3. Clinical response and clinical parameters such as age, menstrual status, size,  
Stage and Immunohistochemistry 
 
 Good Clinical 
response    (%) 
aPoor clinical  
response(%) 
Total 






























































     2 
     3 


































P = .400 
 
aPoor clinical response = Partial response in 40% of the patients +Stable disease in 8.6%  
of the patients+ Progressive disease in 11.4% of the patients. 









Table 4.  Frequency of Side effects 
 
Side effect Number  (%) 
GIT symptoms, Nausea, vomiting, anorexia 29          (82.9) 
Alopecia 33          (94.3) 
Hand and foot hyperpigmentation 33          (94.3) 
Neutropenia 18          (51.4) 
Thrombocytopenia 9            (25.7) 
Anaemia 18          (51.4) 
Cardiac 3             (8.6) 
Neuropathy 4            (11.4) 
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